Is IQYMUNE 100 mg/ml Infusionslösung 100 mg/ml (Infusionslösung) in short supply? — Medicine alert in Austria (Oct 2021)

IQYMUNE 100 mg/ml Infusionslösung 100 mg/ml (Infusionslösung)

📷 EU Safety Watch placeholder

Parallel export of IQYMUNE 100 mg/ml infusion solution is banned. Supply shortages in production mean domestic patient needs cannot be met, despite no distribution restrictions from the marketing authorisation holder. Affected packs: 200 ml and 100 ml vials, available under §4(1) since 4 October 2021, with next resupply on 31 December 2026.

🗄

Archived (older alert)

This alert was reported 1759 days ago and has been moved from our active feed to the archive. The original safety information still applies — we have no confirmation from the issuing agency that the product is safe again. Refer to the official notice for the current status.

📈 Timeline

72 days in total

May 18, 2026 July 29, 2026

Daily snapshot data starts accumulating once the scheduler runs — for now this is interpolated from the agency's first/last dates.

What is this? This is a medicine called IQYMUNE. It is an infusion (a liquid given through a vein) that contains immunoglobulin, which helps the body fight infections.

What's happening? There is a shortage of this medicine in Austria. The company cannot make enough to meet the need.

Does this affect me? If you use this medicine, you may have trouble getting it. Ask your doctor or pharmacist for help.

What should I do? Talk to your pharmacist or doctor before making any changes. They can suggest other options if needed.

🤖 This plain-language summary is automatically generated from the official agency notice using AI. It is for general information only — not medical advice. For decisions about your health, always consult a pharmacist or doctor and read the official source linked below.

🔬 Medical / technical details (for professionals)

Active substance(s)

IMMUNGLOBULIN

Agency-published detail

🚫 Parallel export ban active · ATC: J06BA02 · Reason: Kapazitätsengpässe bei der Herstellung · Marketing authorisation holder: Laboratoire Francais Du Fractionnement Et Des Biotechnologies, Zone D Activite De Courtaboeuf 3 Avenue Des Tropiques -, 91940 Les Ulis, French Republic · BASG note: Es handelt sich hierbei um ein Verfahren gemäß § 4 Abs. 1 der Verordnung über die Sicherstellung der Arzneimittelversorgung. Der Bedarf der Patientinnen und Patienten im Inland kann mit dieser Arzneispezialität nicht gedeckt werden, obwohl nach Angaben des Zulassungsinhabers keine Einschränkung der Vertriebsfähigkeit vorliegt. · Affected packs: 200 ml Durchstechflasche [verfügbar gemäß §4 (1), since 2021-10-04, resupply 2026-12-31] · 100 ml Durchstechflasche [verfügbar gemäß §4 (1), since 2021-10-04, resupply 2026-12-31]

First published

October 4, 2021

Last refreshed by us

2 months ago

Severity (as classified)

Low

Official source

https://medikamente.basg.gv.at/en/medicine-shortage

All information on this page comes from the official agency notice. We translate and summarise it; we don't add or edit facts.

❓ Frequently asked questions

▸ What is this medicine shortage alert about?

IQYMUNE 100 mg/ml Infusionslösung 100 mg/ml (Infusionslösung). Parallel export of IQYMUNE 100 mg/ml infusion solution is banned. Supply shortages in production mean domestic patient needs cannot be met, despite no distribution restrictions from the marketing authorisation holder. Affected packs: 200 ml and 100 ml vials, available under §4(1)...

▸ When was this alert issued?

This alert was issued on October 4, 2021 by BASG (Austria).

▸ Which countries are affected?

The alert applies to Austria.

▸ How serious is this alert?

Low risk. A low risk means harm is unlikely under normal use. The alert is informational but still worth reading.

▸ What should I do?

If you take this medicine, contact your pharmacist or prescribing doctor. They can advise on alternative products or substitutes. Do not stop taking prescription medicine without medical advice.

▸ Where can I find the official notice?

The full official notice is published on medikamente.basg.gv.at.

💬 Discussion

Share your experience or ask a question. Real names and email are optional but moderation friendly.

No comments yet — be the first.